Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B I Eriksson

Showing results (71-80 of 76) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 76 results.
Journal of Thrombosis and Haemostasis : JTH|January 7, 2005
A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trialB I Eriksson, O E Dahl, H R Büller, et al.
Thrombosis Research|May 4, 2010
Dabigatran versus enoxaparin for prevention of venous thromboembolism after hip or knee arthroplasty: a pooled analysis of three trialsR J Friedman, O E Dahl, N Rosencher, et al.
Thrombosis Research|May 20, 2008
Safety assessment of new antithrombotic agents: lessons from the EXTEND study on ximelagatranG Agnelli, B I Eriksson, A T Cohen, et al.
Journal of Thrombosis and Haemostasis : JTH|December 17, 2003
The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS studyB I Eriksson, G Agnelli, A T Cohen, et al.
Journal of Thrombosis and Haemostasis : JTH|September 4, 2007
Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trialB I Eriksson, O E Dahl, N Rosencher, et al.
International Angiology : a Journal of the International Union of Angiology|February 16, 2008
Major joint replacement. A model for antithrombotic drug development: from proof-of-concept to clinical useO E Dahl, L C Borris, D Bergqvist, et al.
Pageof 8

Showing results (71-80 of 76) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 76 results.
Journal of Thrombosis and Haemostasis : JTH|January 7, 2005
A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trialB I Eriksson, O E Dahl, H R Büller, et al.
Thrombosis Research|May 4, 2010
Dabigatran versus enoxaparin for prevention of venous thromboembolism after hip or knee arthroplasty: a pooled analysis of three trialsR J Friedman, O E Dahl, N Rosencher, et al.
Thrombosis Research|May 20, 2008
Safety assessment of new antithrombotic agents: lessons from the EXTEND study on ximelagatranG Agnelli, B I Eriksson, A T Cohen, et al.
Journal of Thrombosis and Haemostasis : JTH|December 17, 2003
The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS studyB I Eriksson, G Agnelli, A T Cohen, et al.
Journal of Thrombosis and Haemostasis : JTH|September 4, 2007
Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trialB I Eriksson, O E Dahl, N Rosencher, et al.
International Angiology : a Journal of the International Union of Angiology|February 16, 2008
Major joint replacement. A model for antithrombotic drug development: from proof-of-concept to clinical useO E Dahl, L C Borris, D Bergqvist, et al.
Pageof 8